by Elana Gotkine For patients with moderate-to-severe plaque psoriasis, the interleukin-23-receptor antagonist peptide JNJ-77242113 shows greater efficacy than placebo, according to a study published in the Feb. 8 issue of the New England Journal of Medicine. Robert Bissonnette, M.D., from Innovaderm Research in Montreal, and colleagues conducted a phase 2 dose-finding trial involving 255 patients...
Tag: <span>plaque psoriasis</span>
Post
Arcutis pulls in a win for its topical version of an old AstraZeneca drug in plaque psoriasis
Make way, Dermavant. Two months after the company vowed to upend the plaque psoriasis market with its newly approved vanishing cream, there’s another topical to contend with. Arcutis Biotherapeutics secured a win on Friday for its phosphodiesterase-4 (PDE4) inhibitor roflumilast, now marketed as Zoryve in plaque psoriasis for children and adults ages 12 and up....
Post
Benvitimod cream: a new topical treatment for plaque psoriasis
CACTUS COMMUNICATIONS IMAGE: THE NOVEL NON-STEROIDAL CREAM, BENVITIMOD, CAN SAFELY AND EFFECTIVELY TREAT PSORIASIS OVER THE LONG TERM WITHOUT SIDE-EFFECTS CREDIT: PEXELS Psoriasis is a chronic inflammatory skin disease characterized by erythematous (red) patches and plaques. In some patients, psoriasis may be associated with comorbidities such as arthritis, obesity, diabetes, cardiovascular diseases, hyperlipidemia, or depression....